Possible involvement of oxidative stress in 5-fluorouracil-mediated myelosuppression in mice

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 1, 2011, Pages 40-45

  Numazawa, Satoshi ^a   Sugihara, Kazuko ^a   Miyake, Shota ^a   Tomiyama, Hirono ^a   Hida, Ayako ^a   Hatsuno, Misato ^a   Yamamoto, Masayuki ^b   Yoshida, Takemi ^a  

^a SHOWA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; FLUOROURACIL; GLUTATHIONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEME OXYGENASE 1; MESSENGER RNA; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; FEMUR; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ACETYLCYSTEINE; ANIMALS; BONE MARROW; ENZYME INDUCTION; FLUOROURACIL; GLUTATHIONE; HEME OXYGENASE-1; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS;

MUS;

EID: 78650198483     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00621.x     Document Type: Article

References (36)

1. Hosseinimehr SJ, Karami M. Chemoprotective effects of captopril against cyclophosphamide-induced genotoxicity in mouse bone marrow cells. Arch Toxicol 2005;79:482-6.
2. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999;31:971-97.
3. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997;11:931-6.
4. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
5. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.
6. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000;356:1384-91.
7. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.
8. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7:288-323.
9. Friberg LE, Karlsson MO. Mechanistic models for myelosuppression. Invest New Drugs 2003;21:183-94.
10. Cancelas JA, Koevoet WL, de Koning AE, Mayen AE, Rombouts EJ, Ploemacher RE. Connexin-43 gap junctions are involved in multiconnexin-expressing stromal support of hemopoietic progenitors and stem cells. Blood 2000;96:498-505.
11. Subrahmanyam VV, Ross D, Eastmond DA, Smith MT. Potential role of free radicals in benzene-induced myelotoxicity and leukemia. Free Radic Biol Med 1991;11:495-515.
12. Numazawa S, Yoshida T. Nrf2-dependent gene expressions: a molecular toxicological aspect. J Toxicol Sci 2004;29:81-9.
13. Itoh K, Tong KI, Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med 2004;36:1208-13.
14. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236:313-22.
15. Anderson ME. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 1985;113:548-55.
16. Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001;59:169-77.
17. Umemura T, Kuroiwa Y, Kitamura Y, Ishii Y, Kanki K, Kodama Y et al. A crucial role of Nrf2 in in vivo defense against oxidative damage by an environmental pollutant, pentachlorophenol. Toxicol Sci 2006;90:111-9.
18. Lamle J, Marhenke S, Borlak J, von Wasielewski R, Eriksson CJ, Geffers R et al. Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology 2008;134:1159-68.
19. Yoh K, Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 2008;13:1159-70.
20. Liu M, Grigoryev DN, Crow MT, Haas M, Yamamoto M, Reddy SP et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 2009;76:277-85.
21. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, Kong AN. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 2006;66:11580-4.
22. Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO et al. Inhibition of 7, 12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res 2006;66:8293-6.
23. Shih AY, Imbeault S, Barakauskas V, Erb H, Jiang L, Li P et al. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 2005;280:22925-36.
24. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 2009;106:2933-8.
25. Chan K, Kan YW. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci U S A 1999;96:12731-6.
26. Cho HY, Reddy SP, Yamamoto M, Kleeberger SR. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 2004;18:1258-60.
27. Aoki Y, Hashimoto AH, Amanuma K, Matsumoto M, Hiyoshi K, Takano H et al. Enhanced spontaneous and benzo(a)pyrene-induced mutations in the lung of Nrf2-deficient gpt delta mice. Cancer Res 2007;67:5643-8.
28. Lorenz M, Slaughter HS, Wescott DM, Carter SI, Schnyder B, Dinchuk JE et al. Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp Hematol 1999;27:1494-502.
29. Dinarello CA. Biology of interleukin 1. FASEB J 1988;2:108-15.
30. Futami H, Jansen R, MacPhee MJ, Keller J, McCormick K, Longo DL et al. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy. J Immunol 1990;145:4121-30.
31. Zhu H, Zhang L, Itoh K, Yamamoto M, Ross D, Trush MA et al. Nrf2 controls bone marrow stromal cell susceptibility to oxidative and electrophilic stress. Free Radic Biol Med 2006;41:132-43.
32. Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57:293-308.
33. Millea PJ. N-acetylcysteine: multiple clinical applications. Am Fam Physician 2009;80:265-9.
34. Suzuki K. Anti-oxidants for therapeutic use: why are only a few drugs in clinical use? Adv Drug Deliv Rev 2009;61:287-9.
35. Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006;98:236-44.
36. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 2004;309:594-9.